T. Fujioka et al., INHIBITION OF TUMOR-GROWTH AND ANGIOGENESIS BY VITAMIN-D3 AGENTS IN MURINE RENAL-CELL CARCINOMA, The Journal of urology, 160(1), 1998, pp. 247-251
Purpose: To investigate the effect of active vitamin D3(VD) agents on
tumor growth and metastasis. Materials and Methods: BALB/c mice were i
noculated with murine renal cancer Renca and graded doses of 1,25-dehy
drovitamin D3 or 1-hydrovitamin D3 were given intraperitoneally every
other day beginning on day 1, 3, or 7 and ending on day 9, 11, or 15.
Direct cytocidal activity and angiogenic activity were evaluated by 48
-hour MTT assay and by the colorimetric method, respectively. Results:
Both VD agents inhibited tumor growth and prolonged the life span of
Renca-bearing mice in a dose-dependent manner and both suppressed tumo
r growth in athymic mice and euthymic mice with eliminated NK activity
. Marginal body-weight loss without appreciable hypercalcemia was obse
rved in mice given VD agents. When treatment was delayed on day 7, the
VD agents failed to inhibit tumor growth. The MTT assay showed no dir
ect cytotoxicity of VD agents on Renca. Tumor angiogenesis was inhibit
ed to 46 to 30% of the control level by VD agents. Furthermore, VD age
nts reduced pulmonary and hepatic foci in the metastatic models. Concl
usions: These results suggest that VD agents may be effective as a tre
atment for renal cell carcinoma, especially when micrometastases are i
nvolved.